FGFR3 / CD333 recombinant protein

Recombinant Mouse FGFR3 / CD333 Protein (His tag)

Cat. Num. AAA2547238

• Gene Names: Fgfr3; FR3; Mfr3; sam3; CD333; Flg-2; HBGFR; Fgfr-3
• Purity: > 98 % as determined by SDS-PAGE
• Synonyms: FGFR3 / CD333; Recombinant Mouse FGFR3 / CD333 Protein (His tag); Fgfr3; Fgfr-3; HBGFR; FGFR3 / CD333 recombinant protein

• Host: Human Cells
• Purity/Purification: > 98 % as determined by SDS-PAGE
• Form/Format: Lyophilized from sterile PBS, pH 7.4
• Sequence Length: 800

• Application Notes: The recombinant mouse FGFR3 comprises 358 amino acids and has a calculated molecular mass of 37 kDa. In SDS-PAGE under reducing conditions, the apparent molecular mass of rmFGFR3 is approximately 70-80 kDa due to glycosylation.
• Predicted N Terminal: Glu 21
• Endotoxin: < 1.0 EU per mug of the protein as determined by the LAL method
• Preparation and Storage: Samples are stable for up to twelve months from date of receipt at -70 degree C

Related Product Information for FGFR3 / CD333 recombinant protein

Background: FGFR3, also known as CD333, is a member of the fibroblast growth factor receptor (FGFR) family, with its amino acid sequence being highly conserved between members and among divergent species. FGFR family members differ from one another in their ligand affinities and tissue distribution. FGFRs are transmembrane catalytic receptors that have intracellular tyrosine kinase activity. Mutations in FGFR genes are the cause of several human developmental disorders characterized by skeletal abnormalities such as achondroplasia, and upregulation of FGFR expression may lead to cell transformation and cancer. FGFR3, a full-length representative protein would consist of an extracellular region, composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. The extracellular portion of FGFR3 interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. FGFR3 binds acidic and basic fibroblast growth hormone and plays a role in bone development and maintenance. Mutations in FGFR3 gene lead to craniosynostosis and multiple type s of skeletal dysplasia. Three alternatively spliced transcript variants that encode different protein isoforms have been described. CD333 is the receptor for acidic and basic fibroblast growth factors.

Description: A DNA sequence encoding the extracellular domain (Met 1-Tyr 367) of mouse FGFR3 (NP_032036.2) was expressed, fused with a polyhistidine tag at the C-terminus.

NCBI and Uniprot Product Information

• NCBI GI #: 46877057
• NCBI GeneID: 14184
• NCBI Accession #: NP_032036.2
• NCBI GenBank Nucleotide #: NM_008010.5
• UniProt Accession #: Q61851; Q61564; Q63834
• Molecular Weight: 88,246 Da
• NCBI Official Full Name: fibroblast growth factor receptor 3 isoform 1
• NCBI Official Synonym Full Names: fibroblast growth factor receptor 3
• NCBI Official Symbol: Fgfr3
• NCBI Official Synonym Symbols: FR3; Mfr3; sam3; CD333; Flg-2; HBGFR; Fgfr-3
• NCBI Protein Information: fibroblast growth factor receptor 3
• UniProt Protein Name: Fibroblast growth factor receptor 3
• UniProt Gene Name: Fgfr3
• UniProt Synonym Gene Names: Mfr3; Sam3; FGFR-3

NCBI Description

This gene encodes a member of the fibroblast growth factor receptor family. Members of this family are highly conserved proteins that differ from one another in their ligand affinities and tissue distribution. A representative protein consists of an extracellular region composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment, and a cytoplasmic tyrosine kinase domain. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. This family member binds acidic and basic fibroblast growth hormone and plays a role in bone development and maintenance. Mutations in this gene may be associated with craniosynostosis and multiple types of skeletal dysplasia. A pseudogene of this gene is located on chromosome 1. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene. [provided by RefSeq, Apr 2011]

Uniprot Description

FGFR3: a receptor tyrosine kinase of the highly-conserved FGFR family that binds fibroblast growth factor (FGF). Mutations are associated with thanatophoric dysplasia (TD), craniosynostosis Adelaide type, many craniosynostotic syndromes and bone malformations. Three splice-variant isoforms have been described. Activating point mutations cause dwarfism, including achondroplasia, hypochrondroplasia and thanatophoric dysplasia, and facial and other morphogenetic disorders, including Crouzon syndrome, craniosynostosis Adelaide type, San Diego skeletal displasia and Muenke syndrome. Translocations t(4;14) involving the IgH region are common in multiple myeloma and frequently involve FGFR3. Activated FGFR3 found in 30% of bladder cancers and several cervical cancers, but not in other tumors. Two mutations found in colorectal cancer.

Protein type: EC 2.7.10.1; FGFR family; Kinase, protein; Membrane protein, integral; Protein kinase, TK; Protein kinase, tyrosine (receptor); TK group

Chromosomal Location of Human Ortholog: 5 B2|5 17.83 cM

Cellular Component: cell surface; cytoplasm; endoplasmic reticulum; Golgi apparatus; integral to plasma membrane; internal side of plasma membrane; lysosome; nucleus; perinuclear region of cytoplasm; plasma membrane; transport vesicle

Molecular Function: fibroblast growth factor binding; fibroblast growth factor receptor activity; protein binding; protein-tyrosine kinase activity

Biological Process: bone mineralization; cartilage development; cell differentiation; cell-cell signaling; digestive tract morphogenesis; fibroblast growth factor receptor signaling pathway; forebrain development; inner ear development; inner ear receptor cell differentiation; lens morphogenesis in camera-type eye; MAPKKK cascade; morphogenesis of an epithelium; myelination in the central nervous system; negative regulation of astrocyte differentiation; negative regulation of cell proliferation; negative regulation of developmental growth; negative regulation of epithelial cell proliferation; negative regulation of mitosis; negative regulation of smoothened signaling pathway; negative regulation of transcription from RNA polymerase II promoter; oligodendrocyte development; peptidyl-tyrosine phosphorylation; positive regulation of bone mineralization; positive regulation of cell differentiation; positive regulation of cell proliferation; positive regulation of endothelial cell proliferation; positive regulation of MAPKKK cascade; positive regulation of neuron apoptosis; positive regulation of peptidyl-tyrosine phosphorylation; positive regulation of phosphoinositide 3-kinase activity; positive regulation of protein ubiquitination; positive regulation of tyrosine phosphorylation of Stat1 protein; positive regulation of tyrosine phosphorylation of Stat3 protein; protein amino acid autophosphorylation; regulation of bone remodeling; regulation of ossification; regulation of osteoclast differentiation; response to axon injury; somatic stem cell maintenance; substantia nigra development